What Lies Ahead For Clinical Trial Sponsors And Partners?

By Ed Miseta, Chief Editor, Clinical Leader

What lies ahead in the next 12 months for clinical trial firms and their drug partners? A new report by the Drug Information Association (DIA) looks ahead to see the trends that will affect these firms. The report discusses the growth of atypical partnerships, market access, transparency, partner relationships, big data, and FDA requirements.

Susan Cantrell, direcotr, North America for DIA, and Adam Istas, member of the DIA Advisory Council of North America, discuss these trends and the impact we can expect them to have on the pharma industry.